Intrinsic Edge Capital Management LLC Sells 11,946 Shares of Vericel Co. (NASDAQ:VCEL)

Intrinsic Edge Capital Management LLC lessened its holdings in Vericel Co. (NASDAQ:VCEL) by 10.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,398 shares of the biotechnology company’s stock after selling 11,946 shares during the period. Intrinsic Edge Capital Management LLC owned about 0.20% of Vericel worth $5,348,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VCEL. Lord Abbett & CO. LLC bought a new position in Vericel during the 4th quarter valued at $6,193,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Vericel during the fourth quarter valued at about $3,943,000. Syon Capital LLC purchased a new position in Vericel during the fourth quarter worth about $257,000. Hsbc Holdings PLC bought a new stake in Vericel in the 4th quarter worth about $405,000. Finally, Stifel Financial Corp grew its position in Vericel by 23.6% in the 4th quarter. Stifel Financial Corp now owns 34,705 shares of the biotechnology company’s stock worth $1,906,000 after purchasing an additional 6,632 shares in the last quarter.

Vericel Stock Performance

Shares of VCEL opened at $39.73 on Friday. The firm has a market cap of $1.99 billion, a P/E ratio of 662.28 and a beta of 1.61. Vericel Co. has a fifty-two week low of $37.76 and a fifty-two week high of $63.00. The business has a 50-day moving average of $45.76 and a 200 day moving average of $51.28.

Insider Transactions at Vericel

In other news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the sale, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,942 shares of company stock worth $2,724,548 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on VCEL. Truist Financial cut their target price on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group raised their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus target price of $60.86.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.